CN115667300A - 猫抗体变异体 - Google Patents

猫抗体变异体 Download PDF

Info

Publication number
CN115667300A
CN115667300A CN202180028968.3A CN202180028968A CN115667300A CN 115667300 A CN115667300 A CN 115667300A CN 202180028968 A CN202180028968 A CN 202180028968A CN 115667300 A CN115667300 A CN 115667300A
Authority
CN
China
Prior art keywords
igg
constant domain
antibody
substitution
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028968.3A
Other languages
English (en)
Chinese (zh)
Inventor
L·M·伯杰龙
H·L·坎波斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis Services LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services LLC filed Critical Zoetis Services LLC
Publication of CN115667300A publication Critical patent/CN115667300A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180028968.3A 2020-04-17 2021-04-16 猫抗体变异体 Pending CN115667300A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011491P 2020-04-17 2020-04-17
US63/011,491 2020-04-17
PCT/US2021/027839 WO2021212084A1 (en) 2020-04-17 2021-04-16 Feline antibody variants

Publications (1)

Publication Number Publication Date
CN115667300A true CN115667300A (zh) 2023-01-31

Family

ID=75870744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028968.3A Pending CN115667300A (zh) 2020-04-17 2021-04-16 猫抗体变异体

Country Status (17)

Country Link
US (2) US20240067730A1 (https=)
EP (1) EP4136109A1 (https=)
JP (1) JP2023522030A (https=)
KR (1) KR20230005158A (https=)
CN (1) CN115667300A (https=)
AU (1) AU2021257355A1 (https=)
BR (1) BR112022020631A2 (https=)
CA (1) CA3176434A1 (https=)
CL (2) CL2022002856A1 (https=)
CO (1) CO2022014684A2 (https=)
EC (1) ECSP22080858A (https=)
IL (1) IL297290A (https=)
MX (1) MX2022012793A (https=)
PE (1) PE20230348A1 (https=)
PH (1) PH12022552743A1 (https=)
TW (1) TW202204404A (https=)
WO (1) WO2021212084A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
US11542333B2 (en) 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US11434276B2 (en) 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
CN115702169A (zh) * 2020-06-10 2023-02-14 株式会社梅花治疗 包含促红细胞生成素多肽的融合蛋白
EP4178977A1 (en) 2020-07-10 2023-05-17 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
AR123645A1 (es) * 2020-09-29 2022-12-28 Zoetis Services Llc Variantes de anticuerpos felinos
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163699A1 (en) * 2004-11-12 2009-06-25 Chamberlain Aaron Keith Fc VARIANTS WITH ALTERED BINDING TO FcRn
US20130022616A1 (en) * 2011-07-21 2013-01-24 Pfizer Inc. Interleukin-31 Monoclonal Antibody
CN110769851A (zh) * 2017-02-24 2020-02-07 金德雷德生物科学股份有限公司 兽用抗il31抗体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
RU2529951C2 (ru) * 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163699A1 (en) * 2004-11-12 2009-06-25 Chamberlain Aaron Keith Fc VARIANTS WITH ALTERED BINDING TO FcRn
US20130022616A1 (en) * 2011-07-21 2013-01-24 Pfizer Inc. Interleukin-31 Monoclonal Antibody
CN110769851A (zh) * 2017-02-24 2020-02-07 金德雷德生物科学股份有限公司 兽用抗il31抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ATSUHIKO MAEDA等: "Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody", MABS, vol. 9, no. 5, 4 July 2017 (2017-07-04), pages 844 - 853 *
CATHERINE J. STRIETZEL等: "In Vitro functional characterization of feline IgGs", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 158, no. 3, 15 April 2014 (2014-04-15), pages 214 - 223 *
M.E. GRUEN等: "A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study", JOURNAL OF VETERINARY INTERNAL MEDICINE, vol. 30, no. 4, 1 July 2016 (2016-07-01), pages 1138 - 1148 *

Also Published As

Publication number Publication date
EP4136109A1 (en) 2023-02-22
KR20230005158A (ko) 2023-01-09
CA3176434A1 (en) 2021-10-21
BR112022020631A2 (pt) 2022-11-29
AU2021257355A1 (en) 2022-11-03
US20250026834A1 (en) 2025-01-23
TW202204404A (zh) 2022-02-01
US20240067730A1 (en) 2024-02-29
CO2022014684A2 (es) 2022-11-08
CL2023003376A1 (es) 2024-04-19
WO2021212084A1 (en) 2021-10-21
PE20230348A1 (es) 2023-03-02
CL2022002856A1 (es) 2023-06-02
MX2022012793A (es) 2022-11-07
PH12022552743A1 (en) 2024-03-25
IL297290A (en) 2022-12-01
JP2023522030A (ja) 2023-05-26
ECSP22080858A (es) 2023-01-31

Similar Documents

Publication Publication Date Title
CN115667300A (zh) 猫抗体变异体
TW202204403A (zh) 犬抗體變異體
CN116547298A (zh) 猫抗体恒定区中的突变
CN116615463A (zh) 牛抗体变体
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
CN116438196A (zh) 犬抗体变体
TWI880316B (zh) 貓抗體變異體
RU2840969C1 (ru) Варианты кошачьих антител
RU2858900C2 (ru) Варианты кошачьих антител
US12612455B2 (en) Feline antibody variants
RU2847183C1 (ru) Варианты собачьих антител
CN119365494A (zh) 犬抗体突变体
BR122024007417A2 (pt) Igg modificada, composição farmacêutica, kit, polipeptídeo, vetor, célula isolada, molécula de fusão, imunoglobulina, seu uso, bem como método de fabricação de um anticorpo ou uma molécula
BR122024006370A2 (pt) Polipeptídeo, seu uso, composição farmacêutica, kit, igg modificada, vetor, célula isolada, molécula de fusão, e seu método de fabricação
CN119730881A (zh) 牛抗体突变体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination